Bank of New York Mellon Corp Sells 52,090 Shares of Hologic, Inc. (NASDAQ:HOLX)

Bank of New York Mellon Corp cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 1,433,974 shares of the medical equipment provider's stock after selling 52,090 shares during the quarter. Bank of New York Mellon Corp owned 0.64% of Hologic worth $88,577,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in HOLX. Dark Forest Capital Management LP boosted its stake in Hologic by 7.9% in the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 223 shares during the period. Baker Avenue Asset Management LP boosted its stake in Hologic by 0.5% in the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after purchasing an additional 225 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Integrated Advisors Network LLC boosted its stake in Hologic by 5.4% in the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock worth $346,000 after purchasing an additional 289 shares during the period. Finally, J. Safra Sarasin Holding AG boosted its stake in Hologic by 4.3% in the 4th quarter. J. Safra Sarasin Holding AG now owns 7,150 shares of the medical equipment provider's stock worth $515,000 after purchasing an additional 293 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Performance

NASDAQ HOLX traded down $1.10 during midday trading on Monday, hitting $64.62. The company had a trading volume of 1,691,160 shares, compared to its average volume of 2,388,663. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The stock has a market cap of $14.40 billion, a price-to-earnings ratio of 27.27, a P/E/G ratio of 2.41 and a beta of 0.55. The firm has a fifty day simple moving average of $61.55 and a two-hundred day simple moving average of $63.41. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period last year, the business posted $1.03 EPS. The business's quarterly revenue was down 1.2% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director owned 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on HOLX. Evercore ISI raised their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and increased their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Morgan Stanley cut their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Finally, Stephens cut their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Hologic has a consensus rating of "Hold" and an average price target of $78.75.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.